<DOC>
	<DOCNO>NCT01221818</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single oral ascending dos E6007 healthy subject .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled , Ascending Single Dose Study E6007 Healthy Subjects</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , ascend single dose study evaluate safety tolerability E6007 healthy subject . Six dose group evaluate . Subjects receive either 25 mg , 50 mg , 100 mg , 200 mg , 400 mg , 600 mg E6007 match placebo tablet . Subjects undergo screen evaluation , baseline evaluation , Day 1 ( dose day ) , Days 2-5 evaluation . They also follow-up visit Day 90 Day 180 follow-up phone call .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Inclusion criterion : â€¢ Healthy , nonsmoking , male female subject age 1855 year old body mass index ( BMI ) 18 30 kg/m2 time screen Evidence clinically significant infection , hepatic , gastrointestinal , renal , respiratory , endocrine , hematological , neurological , psychiatric , rheumatologic , musculoskeletal system abnormality base medical history , physical examination , screen lab assessment History gastrointestinal surgery could impact absorption drug Evidence clinically significant cardiovascular abnormality Family history sudden death attribute cardiac arrhythmia QTc problem , additional risk factor torsades de pointes ( TdP ) ( eg , heart failure , hypokalemia , family history long QT syndrome ) Known suspect history drug alcohol misuse within 6 month prior screen , positive drug alcohol test Positive hepatitis B C screen Screening laboratory value outside normal range diagnose acquire immune deficiency syndrome ( AIDS ) , test positive human immunodeficiency virus ( HIV ) Evidence clinically significant deviation normal physical examination , vital sign , clinical laboratory assessment screen Known history significant drug food allergy ongoing seasonal allergy Known neurological psychiatric disorder could impact neurological assessment Known history autoimmune disease History cancer Participated another clinical trial le 4 week prior dose Subjects receive blood product within 4 week , donate blood within 8 week donate plasma within 1 week dose Subjects take dietary supplement ( include vitamin ) , juice , herbal preparation food beverage may affect various drug metabolize enzyme transporter ( eg , alcohol , grapefruit , grapefruit juice charbroiled meat ) within 1 week prior dose Subjects use prescription drug within 4 week prior dose overthecounter ( OTC ) medication within 1 week prior dose Subjects perform strenuous physical activity exercise within 1 week prior dose Subjects answer affirmatively follow question Study Entry Questionnaire : ( 1 ) Do medical condition may make body unable fight infection like leukemia , lymphoma , human immunodeficiency virus ( HIV ) , organ transplant ? ( 2 ) Over last 4 week treat cancer and/or autoimmune disease ; ( 3 ) Have ever take natalizumab , rituximab , efalizumab , alemtuzumab , mycophenolate , immunosuppressive agent know associated Progressive Multifocal Leukoencephalopathy ( PML ) ? ( 4 ) Have take follow medicine last 12 month : dexamethasone , bethamethasone , methylprednisolone , budesonide , prednisone , methotrexate , cyclosporine , tacrolimus , enbrel , humira , remicade , azathioprine , 6MP , chemotherapyrelated drug , antitumor necrosis factor ( TNF ) alpha agent , immunosuppressive agent associate Progressive Multifocal Leukoencephalopathy ( PML ) natalizumab , rituximab , efalizumab , alemtuzumab , mycophenolate ? Positive John Cunningham Polyomavirus ( JCV ) blood deoxyribonucleic acid ( DNA ) polymerase chain reaction ( PCR ) test result Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>